Searchable abstracts of presentations at key conferences in endocrinology

ea0036oc5.2 | Oral Communications 5 | BSPED2014

The impact of receiving a diagnosis of congenital hypothyroidism on families

Alvi Sabah , Priestley Julia , Whitehead Amanda , Walker Jenny , Mushtaq Talat

Background: Congenital hypothyroidism (CHT) may be viewed as a relatively easy condition to diagnose and treat. However, for the parents who are contacted with the neonatal screening results the news can be devastating. The quality of information provided at diagnosis is variable, and there are few support groups they can turn to. Many seek information online before meeting a paediatrician.Methods: The British Thyroid Foundation in conjunction with our r...

ea0027oc2.4 | Oral Communications 2 (Quick Fire) | BSPED2011

Short term effects of recombinant IGF1 therapy in children with Laron's syndrome

Amin Nadia , Alvi Sabah , Walker Jenny , Whitehead Amanda , Mushtaq Talat

Introduction: Children with Laron’s syndrome have a classical phenotype which includes extreme short stature and mid facial hypoplasia. It is biochemically characterised by high levels of GH and very low IGF1 levels. These children fulfil the criteria for recombinant IGF1 (rhIGF1, Mecasermin) therapy, however this has to be balanced with possible side effects. This study looked at the short term efficacy and safety profile of six children (five males) with Laron’s sy...

ea0030oc5.3 | Oral Communications 5 | BSPED2012

A comparison of patient's preferences for attributes of GH delivery devices: children starting versus children established on GH treatment

Yaw Stephanie How , Mushtaq Talat , Alvi N S , Walker Jenny , Whitehead Amanda

Background: Several devices are available for the administration of recombinant GH. A prospective study was undertaken to look at those attributes of GH delivery device most important to patients when making their choice.Objectives: i) To understand which features of a GH device are considered most important to patients when choosing a device. ii) Comparison of patient’s device preferences at start of GH treatment and after 2 years of treatment. iii...